Want to see SE:CEVI full AI Analyst Report?
CEVI Stock Chart & Stats
kr140.00
kr1.80(1.29%)
At close: 4:00 PM EDT
kr140.00
kr1.80(1.29%)
Day’s Range― - ―
52-Week Rangekr117.60 - kr192.20
Previous CloseN/A
Volume12.68K
Average Volume (3M)36.08K
Market Cap
kr3.90B
Enterprise Valuekr3.13K
Total Cash (Recent Filing)kr172.19M
Total Debt (Recent Filing)kr52.27M
Price to Earnings (P/E)30.9
Beta0.77
Next Earnings
Oct 29, 2026EPS Estimate
1.45Next Dividend Ex-DateN/A
Dividend Yield1.64%
Share Statistics
EPS (TTM)5.41
Shares Outstanding23,851,547
10 Day Avg. Volume30,505
30 Day Avg. Volume36,083
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr150.00Price Target Upside7.14% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)5.93
Revenue Forecast (FY)kr783.83M
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilitySustained high gross and EBIT margins indicate differentiated technology, pricing power and an asset-light business model. This profitability provides capacity to fund product development and absorb moderate regional or cost pressures.
Conservative Balance SheetVery low leverage limits financial risk and preserves flexibility for R&D, commercial expansion and strategic investment. A growing equity base further supports resilience if demand softens or working capital needs increase.
Americas And Product ExpansionStrong Americas demand, instrument refreshes and reagent growth demonstrate adoption across laboratory networks. Continued R&D and the Bone Marrow application can broaden the platform and support durable expansion beyond the core offering.
Bears Say
Recent Revenue DecelerationThe TTM slowdown shows that strong historical growth is not currently translating into consistent acceleration. Lower revenue and margins could constrain operating leverage and make future performance more dependent on new applications and regional recovery.
Free Cash Flow VolatilityAlthough operating cash flow supports earnings quality, uneven free cash flow reduces predictability for reinvestment and shareholder returns. Persistent working-capital needs or higher development spending could keep cash conversion below reported profitability.
APAC And China WeaknessWeak APAC demand, particularly in China, creates a regional growth drag and highlights geographic concentration risk. If challenging market conditions persist, they may offset gains in the Americas and delay a broader recovery in company-wide growth.
CellaVision AB News
CEVI FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was kr117.60 and its highest was kr192.20 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is kr3.90B.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Oct 29, 2026 which is in 65 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Jul 17, 2026. The company reported kr1.37 earnings per share for the quarter, beating the consensus estimate of kr1.339 by kr0.031.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Undervalued.
Does CellaVision AB pay dividends?
CellaVision AB pays a Annually dividend of kr2.75 which represents an annual dividend yield of 1.64%. See more information on CellaVision AB dividends here
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 1.45.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of kr1.37 in its last earnings report, beating expectations of kr1.339. Following the earnings report the stock price went up 7.76%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in SE:CEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
CEVI Company Deck
CEVI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and commercial picture: solid top-line growth (4.5% YoY; ~6% organic), record Americas performance (+≈59% in Americas sales), healthy margins (70% gross margin; 27% EBITDA margin) and progress on strategic initiatives (Bone Marrow launch, FDA 510(k) process, FPM development). Offsetting risks include APAC weakness (notably China), a distributor inventory adjustment in EMEA that depressed near-term sales, increased working capital leading to a negative total cash flow for the quarter, one-time CEO transition costs (SEK 9m) and temporary operational disruptions (SEK 2m delayed reagents). On balance, the positives — strong regional recovery in the Americas, product/reagent momentum in key markets, continued R&D investment and a solid cash buffer — outweigh the transitory and region-specific headwinds.View all SE:CEVI earnings summariesCEVI Stock 12 Month Forecast
Average Price Target
kr150.00
▲(7.14% Upside)
Technical Analysis
BICO Group AB Class B
―
SciBase Holding AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Acarix AB
―